Nalaganje...
Acquired MET D1228N Mutations Mediate Crizotinib Resistance in Lung Adenocarcinoma with ROS1 Fusion: A Case Report
Patients with non‐small cell lung cancer (NSCLC) containing ROS1 fusions can have a marked response to the ROS1‐targeted tyrosine kinase inhibitors (TKIs), such as crizotinib. Common resistance mechanisms of ROS1‐fusion targeted therapy are acquired mutations in ROS1. Along with the use of next‐gene...
Shranjeno v:
| izdano v: | Oncologist |
|---|---|
| Main Authors: | , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
John Wiley & Sons, Inc.
2020
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7930416/ https://ncbi.nlm.nih.gov/pubmed/33000474 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13545 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|